Hemostasis is the procedure of interaction between blood vessels, platelets and coagulation protein to stop bleeding. Sometimes, bleeding disorder occurs due to vascular and coagulation abnormalities. These abnormalities could be inherited or acquired. Acquired disorders are the most common by far, majorly thrombocytopenia and other abnormalities include trauma, anticoagulant rodenticide, vitamin K deficiency, disseminated intravascular coagulation (DIC), Von Willebrand disease (vWD), deficiency of intrinsic and extrinsic factors, dysfibrinogenemia, Monoclonal Gammopathy and congenital platelet function defect. The hemostasis market is segmented into three major categories based on the types of products, as topical hemostats, infusible hemostats and advanced hemostats and sealants. Topical hemostats are further fragmented into three main segments which include:
- Oxidized regenerated cellulose (ORC)
Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2401
Topical hemostats are mostly used in surgery settings for hemostatis. Collagen among these is majorly used as it acts immediately and starts blood clotting by natural pathway. Topical agents are preferred over other agents due to their ease of use, efficiency, biodegradable nature and cost effectiveness. The other major method to treat hemostasis disorder is by using infusible hemostats. The major products which consist of infusible hemostats include:
- Platelet concentrates from donor blood
- FVIII derived from blood
- Fresh frozen plasma
- Prothrombin complex
This method of treatment is used very rarely to treat hemostasis disorder and is used only under some specific conditions. For instance, fresh frozen plasma and prothrombin complex is majorly used to treat severe hemorrhages. Advanced hemostats and sealants market consists of products which have came into existence in recent years and is considered as the best treatment option. Some of the products of this market are still under research pipeline. Advanced hemostats and sealants segment of the hemostasis market includes following categories:
- Synthetic sealants
In the hemostats and sealants market, several formulations of fibrinogen and thrombin have been developed, the most popular and commonly used product being the liquid fibrin sealant product in which the fibrinogen and thrombin are stored separately as lyophilized powder or frozen liquid. The other popular product which has captured large share of market is recothrom by the Medicines Company. Recrothrom is the human recombinant thrombin used as an aid for hemostasis. The market for this segment is increasing rapidly as these products act quickly and are safe in comparison to the topical agents. Topical agents sometimes cause infection leading to fatal consequences.
The hemostasis market is growing at a faster pace with Johnson & Johnson (JNJ) being the major market player. Johnson & Johnson offers distinguished products in hemostasis market under its wholly owned subsidiary Ethicon 360. Ethicon 360’s all products which are under hemostasis product portfolio are approved by the Food and Drug Administration (FDA). Recently, in October 2013, JNJ received clearance from FDA for Harmonic Ace +7, the first ultrasonic surgical devices indicated to seal vessels up to 7 mm. Extensive research and the new innovative products are the major reasons which are helping the market to grow. As recently, Arch Therapeutics, Inc. has developed a revolutionary product to stop bleeding faster than any other product available in market by the name AC5. AC5 is currently in preclinical testing and takes an average time of 15 seconds to stop bleeding in comparison to 80 seconds to 300 seconds taken by other treatments methods.
Some of the market players in Hemostasis market include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens AG, Thermo Fisher Scientific, Inc., Trinity Biotech plc, Chrono-Log Corporation and The Medicines Company.